Yalan He

Yalan He

Auto-generated profile, based on publicly available information

Yalan He

College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in GigaScience
Verified
Journal Article
Open access
YHYalan He
Yalan He
JLJiyin Lai
Jiyin Lai
QWQian Wang
Qian Wang
BPBingyue Pan
Bingyue Pan
SLSiyuan Li
Siyuan Li
JHJunwei Han
Junwei Han
Background: Single-sample pathway enrichment analysis is an effective approach for identifying cancer subtypes and pathway biomarkers, facilitating the development of precision medicine. However, the existing approaches focused on investigating the changes in gene expression levels but neglected somatic mutations, which play a crucial role in cancer development. Findings: In this study, we proposed a novel single-sample mutation-based pathway analysis approach (ssMutPA) to infer individualized pathway activities by integrating somatic mutation data and the protein–protein interaction network. For each sample, ssMutPA first uses local and global weighted strategies to evaluate the effects of genes from mutations according to the network topology and then calculates a single-sample mutation-based pathway enrichment score (ssMutPES) to reflect the accumulated effect of mutations of each pathway. To illustrate the performance of ssMutPA, we applied it to 33 cancer cohorts from The Cancer Genome Atlas database and revealed patient stratification with significantly different prognosis in each cancer type based on the ssMutPES profiles. We also found that the identified characteristic pathways with high overlap across different cancers could be used as potential prognosis biomarkers. Moreover, we applied ssMutPA to 2 melanoma cohorts with immunotherapy and identified a subgroup of patients who may benefit from therapy. Conclusions: We provided evidence that ssMutPA could infer mutation-based individualized pathway activity profiles and complement the current individualized pathway analysis approaches focused on gene expression data, which may offer the potential for the development of precision medicine. ssMutPA is available at https://CRAN.R-project.org/package=ssMutPA.

10 June 2026
Verified
Journal Article
Open access
XLXiangmei Li
Xiangmei Li
YHYalan He
Yalan He
JWJiashuo Wu
Jiashuo Wu
ZWZiyi Wang
Ziyi Wang
XZXilong Zhao
Xilong Zhao
JHJunwei Han
Junwei Han
Immunotherapy has revolutionized cancer treatment, yet substantial inter-patient response heterogeneity limits therapeutic benefit to specific patient subsets. Here, we present PathTIGR, a pathway topology-informed graph representation learning framework that systematically integrates biological pathway network topology knowledge with genome variation information for immunotherapy response prediction. PathTIGR uses a three-component design: (i) pathway graph encoder with multihead attention embeding pathway topology knowledge and cancer genomic variants to pathway representation, (ii) transformer module capturing pathway regulatory dependencies, and (iii) multilayer perceptron synthesizing pathway-level representations to predict immunotherapy response. This architecture enables PathTIGR to capture complex molecular interactions underlying immunotherapy response. Comprehensive validation across multiple independent immunotherapy cohorts demonstrates that PathTIGR achieves superior predictive performance compared to established biomarkers and state-of-the-art deep learning approaches while maintaining biological interpretability through identification of key signatures underlying response heterogeneity. PathTIGR represents an interpretable graph-based learning framework that enhances immunotherapy response prediction and elucidates molecular determinants of therapeutic efficacy, thereby facilitating the advancement of precision cancer immunotherapy.